Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
81
GMED Quote, Financials, Valuation and Earnings
Last price:
$88.77
Seasonality move
:
6.9%
Day range:
$87.20 - $89.13
52-week range:
$51.79 - $94.93
Dividend yield:
0%
P/E ratio:
28.36x
P/S ratio:
4.37x
P/B ratio:
2.67x
Volume:
2M
Avg. volume:
2.1M
1-year change:
5.13%
Market cap:
$11.7B
Revenue:
$2.5B
EPS (TTM):
$3.09
Analysts' Opinion
-
Consensus RatingGlobus Medical, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $91.70, Globus Medical, Inc. has an estimated upside of 4.5% from its current price of $88.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 14.53% downside risk from its current price of $88.74.
Fair Value
-
According to the consensus of 9 analysts, Globus Medical, Inc. has 4.5% upside to fair value with a price target of $91.70 per share.
GMED vs. S&P 500
-
Over the past 5 trading days, Globus Medical, Inc. has underperformed the S&P 500 by -3.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Globus Medical, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Globus Medical, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Globus Medical, Inc. reported revenues of $769M.
Earnings Growth
-
Globus Medical, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Globus Medical, Inc. reported earnings per share of $0.88.
Enterprise value:
11.5B
EV / Invested capital:
2.54x
Price / LTM sales:
4.37x
EV / EBIT:
25.57x
EV / Revenue:
4.14x
PEG ratio (5yr expected):
0.08x
EV / Free cash flow:
20.13x
Price / Operating cash flow:
21.22x
Enterprise value / EBITDA:
15.83x
Gross Profit (TTM):
$1.7B
Return On Assets:
8.44%
Net Income Margin (TTM):
15.3%
Return On Equity:
10.08%
Return On Invested Capital:
9.44%
Operating Margin:
17.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.2B | $2.5B | $2.8B | $625.7M | $769M | |
| Gross Profit | $845.7M | $1.3B | $1.7B | $325.1M | $486.7M | |
| Operating Income | $240.6M | $181.2M | $448.8M | $49M | $134.7M | |
| EBITDA | $331.1M | $438.2M | $724.9M | $115.9M | $205.8M | |
| Diluted EPS | $1.55 | $0.66 | $3.09 | $0.38 | $0.88 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $980.5M | $920M | $1.9B | $2.1B | $1.9B | |
| Total Assets | $1.9B | $2B | $5.4B | $5.1B | $5.1B | |
| Current Liabilities | $122.5M | $145.3M | $428.7M | $818.1M | $466M | |
| Total Liabilities | $192.3M | $212.4M | $1.2B | $1B | $696.8M | |
| Total Equity | $1.7B | $1.8B | $4.2B | $4.1B | $4.4B | |
| Total Debt | $5.4M | -- | $509.7M | $88.1M | $105.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $202.8M | $415M | $715.2M | $203.7M | $249.7M | |
| Cash From Investing | -$78.1M | $248.7M | -$347.7M | -$15M | -$75.8M | |
| Cash From Financing | $19M | -$324.7M | -$632.6M | $19.6M | -$32M | |
| Free Cash Flow | $129.1M | $293.8M | $569.9M | $161.7M | $209.2M | |
GMED
Sector
Market Cap
$11.7B
$28.4M
Price % of 52-Week High
92.44%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
3.14%
-1.32%
1-Year Price Total Return
3.11%
-22.19%
Beta (5-Year)
1.070
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$89.57
200-day SMA
Buy
Level
$65.46
Bollinger Bands (100)
Buy
Level
52.43 - 75.23
Chaikin Money Flow
Buy
Level
61.1M
20-day SMA
Buy
Level
$85.29
Relative Strength Index (RSI14)
Buy
Level
70.77
ADX Line
Buy
Level
46.9
Williams %R
Neutral
Level
-41.5385
50-day SMA
Buy
Level
$70.01
MACD (12, 26)
Buy
Level
5.86
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
86M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.5822)
Buy
CA Score
(Annual)
Level (1.2637)
Buy
Beneish M-Score
(Annual)
Level (-2.581)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.7087)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Stock Forecast FAQ
In the current month, GMED has received 5 Buy ratings 4 Hold ratings, and 0 Sell ratings. The GMED average analyst price target in the past 3 months is $91.70.
-
Where Will Globus Medical, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Globus Medical, Inc. share price will rise to $91.70 per share over the next 12 months.
-
What Do Analysts Say About Globus Medical, Inc.?
Analysts are divided on their view about Globus Medical, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Globus Medical, Inc. is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Globus Medical, Inc.'s Price Target?
The price target for Globus Medical, Inc. over the next 1-year time period is forecast to be $91.70 according to 9 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is GMED A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Globus Medical, Inc. is a Buy. 5 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GMED?
You can purchase shares of Globus Medical, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Globus Medical, Inc. shares.
-
What Is The Globus Medical, Inc. Share Price Today?
Globus Medical, Inc. was last trading at $88.77 per share. This represents the most recent stock quote for Globus Medical, Inc.. Yesterday, Globus Medical, Inc. closed at $88.74 per share.
-
How To Buy Globus Medical, Inc. Stock Online?
In order to purchase Globus Medical, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GMED Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GMED
Sector
P/E ratio
28.36x
23.66x
PEG ratio
0.08x
-0.01x
P/B ratio
2.67x
1.84x
Price / LTM sales
4.37x
1.60x
Growth Metrics
GMED
Sector
Revenue growth
22.91%
4.85%
Earnings growth
134.07%
11.15%
Revenue (5-year growth)
26.25%
6.45%
Earnings forecast
$0.78
-$0.20
Profitability
GMED
Sector
Profitability FY 2024
$1.4B
$3.6M
Return on invested capital
9.44%
-30.98%
Return on assets
8.44%
-27.62%
Return on equity
10.08%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Feb
5
Balance Sheet
GMED
Sector
Total cash
$390.5M
$27.2M
Short term investments
$105.6M
$25.7M
Total assets
$5.3B
$79.9M
Long term debt
$105.8M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 5
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
